Literature DB >> 11672943

Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males.

P N Roset1, M Farré, R de la Torre, M Mas, E Menoyo, C Hernández, J Camí.   

Abstract

Low, medium, and high doses of flunitrazepam were tested in three independent randomized, double-blind, balanced cross-over, placebo-controlled trials to study the influence of rate of onset of effects and dose administered on its acute effects. Three groups of 12 healthy male volunteers received six oral doses of placebo or flunitrazepam in slow and fast onset conditions as follows: six capsules of 0.16 mg (slow) and a single capsule of 0.8 mg (fast) in the low dose trial; six 0.25 mg (slow) and a single 1.25 mg (fast) capsules for medium dose; and six 0.4 mg (slow) and a single 2 mg (fast) capsule for high dose. At each dose level, slow or fast increasing flunitrazepam plasma concentrations lead to similar peak levels, but induced differential subjective and behavioral effects. In addition to objective and subjective sedation, flunitrazepam induced some pleasurable feelings, which were more intense in the fast than in the slow conditions. At the highest dose, unpleasant sedative effects surmounted positive effects, while at the lowest dose pleasurable effects were of low intensity. At the medium dose, the balance between pleasurable and unpleasant feelings resulted in euphorigenic effects, which were evident in the fast condition but were blunted in the slow condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672943     DOI: 10.1016/s0376-8716(01)00127-2

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

1.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

2.  Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.

Authors:  Sean Esteban McCabe; James A Cranford; Carol J Boyd; Christian J Teter
Journal:  Addict Behav       Date:  2006-07-13       Impact factor: 3.913

3.  Drug use related problems among nonmedical users of prescription stimulants: a web-based survey of college students from a Midwestern university.

Authors:  Sean Esteban McCabe; Christian J Teter
Journal:  Drug Alcohol Depend       Date:  2007-07-12       Impact factor: 4.492

Review 4.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

Review 5.  [Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency].

Authors:  R Scharnagel; U Kaiser; A Schütze; R Heineck; G Gossrau; R Sabatowski
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

6.  Incorporating Complex Sample Design Effects When Only Final Survey Weights are Available.

Authors:  Brady T West; Sean Esteban McCabe
Journal:  Stata J       Date:  2012-10-01       Impact factor: 2.637

Review 7.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

8.  Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.

Authors:  Chad J Reissig; Joseph A Harrison; Lawrence P Carter; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2014-09-09       Impact factor: 4.530

9.  Can abuse deterrent formulations make a difference? Expectation and speculation.

Authors:  Simon H Budman; Jill M Grimes Serrano; Stephen F Butler
Journal:  Harm Reduct J       Date:  2009-05-29

10.  Once-daily medications for the pharmacological management of ADHD in adults.

Authors:  Oleg V Tcheremissine; Lori M Lieving
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.